Abstract：
OBJECTIVE: Precision Prostatectomy (PP) is a viable treatment option for men with unilateral dominant cancer who are interested in preserving functional outcomes. To date, the data published about the outcomes of this technique has come from a single center only (Henry Ford - HF). We present the surgical, functional, and oncological outcomes of the first series of patients to undergo PP outside of HF, to demonstrate the safety and reproducibility of the technique.
METHODS: Between 2022 and 2023, PP was offered to select patients who were interested in preserving their functional status. Men who underwent PP were followed at 3 monthly intervals; information regarding their functional status was simultaneously obtained. Men who had biochemical recurrence were advised to undergo remnant biopsy. If residual cancer was detected, then remnant removal was performed.
RESULTS: The median age and median PSA of the study group was 63 years and 6.89 ng/ml respectively. The median operative and console times were 196.5 and 154 minutes. No intra-operative complications were noted. Three patients had a total of three post-operative complications. Three patients had biochemical recurrence; cancer was not detected in any of these patients on postoperative biopsies of the prostatic remnant. At 12 months, 91% of patients reported using 0 pads/day and 90.9% of pre-operatively potent patients were potent at 12 months.
CONCLUSIONS: PP is a safe and reproducible technique that can ensure cancer control and preservation of functional status in select patients. Further studies with large sample sizes and longer follow-up are required to ascertain the long-term outcomes of this surgical technique.
METHODS: Between 2022 and 2023, PP was offered to select patients who were interested in preserving their functional status. Men who underwent PP were followed at 3 monthly intervals; information regarding their functional status was simultaneously obtained. Men who had biochemical recurrence were advised to undergo remnant biopsy. If residual cancer was detected, then remnant removal was performed.
RESULTS: The median age and median PSA of the study group was 63 years and 6.89 ng/ml respectively. The median operative and console times were 196.5 and 154 minutes. No intra-operative complications were noted. Three patients had a total of three post-operative complications. Three patients had biochemical recurrence; cancer was not detected in any of these patients on postoperative biopsies of the prostatic remnant. At 12 months, 91% of patients reported using 0 pads/day and 90.9% of pre-operatively potent patients were potent at 12 months.
CONCLUSIONS: PP is a safe and reproducible technique that can ensure cancer control and preservation of functional status in select patients. Further studies with large sample sizes and longer follow-up are required to ascertain the long-term outcomes of this surgical technique.
摘要：
目的：精准前列腺切除术（PP）是对保留功能预后感兴趣的男性单侧优势癌的可行治疗选择。迄今为止,发表的关于这项技术结果的数据仅来自一个中心（亨利·福特-HF）。我们提出了外科手术，功能，和第一系列患者在HF以外接受PP的肿瘤学结果，以证明该技术的安全性和可重复性。
方法：在2022年至2023年之间，向选择有兴趣保留其功能状态的患者提供PP。每隔3个月对接受PP的男性进行随访；同时获得有关其功能状态的信息。建议生化复发的男性进行残余活检。如果检测到残留的癌症，然后进行残留物去除。
结果：研究组的中位年龄和中位PSA分别为63岁和6.89ng/ml。中位手术时间和控制台时间分别为196.5和154分钟。未发现术中并发症。三名患者共有三个术后并发症。三名患者发生了生化复发；在这些患者的前列腺残留物术后活检中均未检测到癌症。12个月时,91％的患者报告使用0垫/天，90.9％的术前有效患者在12个月时有效。
结论：PP是一种安全且可重复的技术，可以确保某些患者的癌症控制和功能状态的保留。需要进行大样本量和更长时间随访的进一步研究，以确定这种手术技术的长期结果。
方法：在2022年至2023年之间，向选择有兴趣保留其功能状态的患者提供PP。每隔3个月对接受PP的男性进行随访；同时获得有关其功能状态的信息。建议生化复发的男性进行残余活检。如果检测到残留的癌症，然后进行残留物去除。
结果：研究组的中位年龄和中位PSA分别为63岁和6.89ng/ml。中位手术时间和控制台时间分别为196.5和154分钟。未发现术中并发症。三名患者共有三个术后并发症。三名患者发生了生化复发；在这些患者的前列腺残留物术后活检中均未检测到癌症。12个月时,91％的患者报告使用0垫/天，90.9％的术前有效患者在12个月时有效。
结论：PP是一种安全且可重复的技术，可以确保某些患者的癌症控制和功能状态的保留。需要进行大样本量和更长时间随访的进一步研究，以确定这种手术技术的长期结果。
